

August 17, 2026

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001
Scrip Code: 543904

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Symbol: MANKIND

Dear Sir/ Madam,

Ref.: Regulation 30, 51 and other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Subject: Completion of Realignment of Security Cover in respect of Non-Convertible Debentures and Consequent Release of Pledged Shares of Bharat Serums and Vaccines Limited

This is in continuation of our earlier intimation dated May 19, 2026, wherein the Company had inter-alia informed the Stock Exchanges regarding approval by the Board of Directors of the Company for realignment of the security cover in respect of the existing Non-Convertible Debentures ("NCDs") bearing ISIN Nos. INE634S07025 and INE634S07033.

In this regard, we further wish to inform that in accordance with the terms of the Debenture Trust Deed(s) as amended and the applicable provisions of SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021 read with Listing Regulations, as amended, post receipt of requisite approvals of the NCD holders and BSE Limited on July 13, 2026 and on July 21, 2026 respectively, the Company has created the revised security in favour of the Debenture Trustee, viz. Catalyst Trusteeship Limited, over tangible and intangible assets of the Company/its subsidiary(ies). Consequent to creation of the revised security cover as stated above, the pledge on 28,280 equity shares of Bharat Serums and Vaccines Limited ("BSVL") (constituting 38.68% of the paid-up equity share capital of BSVL), which was subsisting in favour of the Debenture Trustee on behalf of the NCD holders, has been released on August 17, 2026. In compliance with the applicable provisions of the Listing Regulations and the terms of the Debenture Trust Deed(s) the revised security cover is 1.26 times the amount of outstanding NCDs as on date. No shares of BSV are now under pledge for NCDs.

The above is submitted for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com